ClinicalTrials.gg
RecruitingNCT06547775Updated Sep 17, 2025

A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight

A Phase 1 interventional study of KN069 in Overweight or Obesity, sponsored by Suzhou Alphamab Co., Ltd.. Recruiting at 1 site in China. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-17.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Suzhou Alphamab Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 603 studies in Obesity with a site in China — 223 open to participants now, 284 under way, 67 of them phase 3. Obesity · China.

Planned enrollment
427th of 504
36 · median 120
Started
2024
with 76 others
Phase 1
93 of 603
29 open now
Primary completion
2027-04
later than 157 of 282 live
Registered
292nd of 603
by date

Among the 603 studies in Obesity with a site in China, this one is the 427th largest by planned enrollment of the 504 interventional ones that give a count, is one of 77 that started in 2024, is one of 93 in phase 1, reaches primary completion later than 157 of the 282 other live ones, and was the 292nd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

223 of the 603 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

218 more — sign in →

All 223 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 603 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

This is a Phase 1, First-in-human, double-blinded, placebo-controlled study which aims to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the immunogenicity of KN069 in Chinese male participants with Obesity or Overweight.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 36 is below the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Suzhou Alphamab Co., Ltd. is the lead sponsor of 10 studies on the registry; 5 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, 18-55 years old (including threshold);
  2. (BMI):24.0 kg/m2≤BMI\<35 kg/m2;
  3. \<6.5%;3.9mmol/L≤Fasting blood glucose level \<7.0mmol/L;
  4. Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures and are willing to follow study restrictions; Are able and willing to sign the ICF.

Exclusion criteria

Exclusion Criteria:

  1. Those who have a history of chronic diseases or are currently suffering from obvious systemic diseases, such as diseases of cardiovascular system, respiratory system, endocrine and metabolic system, urinary system, digestive system, blood system, system, neurological or psychiatric system, bacterial or viral infection;
  2. History of acute or chronic pancreatitis; A personal or family history of medullary thyroid cancer or multiple endocrine adenoma syndrome type 2; A history of other ;
  3. History of GI disorder (for example, relevant esophageal reflux or gall bladder disease) or any GI disease which impacts gastric emptying (for example, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by GLP-1 analogs or DPP-IV inhibitors;
  4. Participants had cholecystolithiasis (removal of gallstones) or cholecystectomy (removal of gall bladder) in the past;
  5. Allergies to KN069 or drugs similar to KN069 in structure or KN069 in the same category;
  6. A history of medicine abuse/dependence or narcotics abuse within 1 year prior to the screening and/or show positive findings on urinary drug screening;
  7. Have undergone any major surgery or surgery affecting drug absorption, distribution, metabolism, excretion within the 3 months prior to screening, or are scheduled to undergo surgery during the trial period (major surgery is defined as surgery on the intracranial, chest, abdomen, pelvic, or limb organs that result in major tissue trauma and require long-term recovery).
  8. Drinking more than 14 units of alcohol per week (1 unit =360ml beer or 45ml liquor with 40% alcohol or 150ml wine) in the 3 months before or during the screening period, alcohol cannot be banned during the hospital stay, and alcohol consumption cannot be limited to less than 2 units of alcohol per day during the post-discharge visit.
  9. Blood donation or blood loss ≥ 300 mL within 3 months prior to screening, or blood/blood components donation planned during the trial or within 1 month after the final study visit.
  10. Received administration of other drugs/vaccines in clinical trials within 2 months prior to screening; In other clinical trials at the time of screening;
  11. People who diet or undergo weight loss treatment within 2 months (for whatever reason) before administration, or who have made significant changes in their lifestyle habits.;
  12. Received vaccination within 14 days prior to screening, or have vaccination schedule during the trial, including inactivated vaccine, , recombinant protein vaccine, recombinant adenovirus vaccine, RNA vaccine, DNA vaccine, COVID-19 vaccine;
  13. Use medication (including prescription drugs, over-the-counter drugs, herbal medicine) with the exception of vitamin/mineral supplements, paracetamol, topical medication, and within 14 days prior to dosing.
  14. Use of GLP-1 analogues, GLP-1 receptor agonists, or any other formulations related to incretin and other drugs that the investigator believes may affect the trial within the 3 months prior to administration.
  15. Any abnormal patients who met the following criteria during screening: 1) serum (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) exceeded the upper limit of the reference value range by 2 times; Serum total (TBIl) exceeded 1.5 times the upper limit of the reference value range; 2) Fasting triglyceride (TG) ≥5.6mmol/L; 3) Physical examination, vital signs, , laboratory examination, imaging and other abnormalities have clinical significance, and the investigator judges that they may pose a major risk to the subjects or interfere with the evaluation of safety, PK or PD results and are not suitable to participate in the trial;
  16. Positive breath test for alcohol (>0 mg/100 mL);
  17. Evidence of ///syphilis.
  18. Urine screen positive for drug abuse.
  19. Participants that refuse to stay abstinent, and refuse to consistently use a form of highly effective birth control method starting at Screening (signing the ICF) and continuing throughout the clinical study period, and to 3 months after administration of IP; or to have a birth plan during the screening period until 3 months after dosing;
  20. Participants that plan to donate sperms from dosing until 3 months after administration of IP.
  21. Due to trauma, surgery, allergies or skin lesions, the abdominal skin is not suitable for subcutaneous injection.
  22. Other factors that the investigator considers unacceptable for participation in the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Group 1: KN069 Dose 1

    Participants will receive a single SC KN069 12mg.

    Drug: KN069

  • Experimental
    Group 2: KN069 Dose 2

    Participants will receive a single SC KN069 30mg.

    Drug: KN069

  • Experimental
    Group 3: KN069 Dose 3

    Participants will receive a single SC KN069 60mg.

    Drug: KN069

  • Experimental
    Group 4: KN069 Dose 4

    Participants will receive a single SC KN069 120mg.

    Drug: KN069

  • Experimental
    Group 5: KN069 Dose 5

    Participants will receive a single SC KN069 240mg.

    Drug: KN069

Interventions

  • DrugKN069

    Solution for SC injection

07

What researchers measure

Primary outcomes

  1. Frequency and severity of adverse events

    Time frame: Up to Day 42

Secondary outcomes

  1. To evaluate the plasma concentration of KN069

    Time frame: Up to Day 42

  2. To evaluate the Area under the plasma concentration versus time curve (AUC) of KN069

    Time frame: Up to Day 42

  3. To evaluate the weight (kg) change from baseline

    Time frame: Up to Day 42

  4. To evaluate the waist circumference (cm) change from baseline

    Time frame: Up to Day 42

  5. To evaluate the BMI (kg/m^2) change from baseline

    Time frame: Up to Day 42

  6. Number of Participants with Anti-KN069 Antibodies

    Time frame: Up to Day 42

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Xie J, Huang J, Wu Q, Deng K, Yang S, Yang S, Wu S, Yang X, Huang W, Dong Y, Li J, Yang G, Guo C. A Phase 1, Randomised, Double-Blind, Placebo-Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 (a Dual GLP-1R Agonist and GIPR Antagonist) in Male Adults With Overweight or Obesity. Diabetes Obes Metab. 2026 Jul;28(7):5848-5859. doi: 10.1111/dom.70794. Epub 2026 Apr 20. PubMed 42010360 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Apr 2027, 32 months after the start.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 32 months is above that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2024
First posted
Aug 9, 2024
StartActual
Aug 2, 2024
Primary completionEst.
Apr 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06547775
Lead sponsor
Suzhou Alphamab Co., Ltd.
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Aug 2, 2024
Primary completion
Apr 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Sep 17, 2025

Study contacts

Yanrong Dong, Master
Contact
yanrongdong@alphamab.com
+86 18914005458 ext. 86
GuoPing Yang, Doctor
principal investigator · Xiangya Third Hospital, Central South University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion